Review decision - November 2025
7 References
Chan K, Wahome E, Tsiachristas A et al. (2024a) Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study. The Lancet 403 (10,444): 2,606–18
Chan K, Wahome E, Tsiachristas A et al. (2024b) To evaluate the prognostic performance of AI-Risk classification among patients with different demographic/socioeconomic backgrounds. (unpublished)
Cholesterol Treatment Trialists' Collaborators (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet, 380 (9,841): 581–590
Oikonomou EK, Antonopoulos A, Schottlander D et al. (2021) Standardized measurement of coronary inflammation using cardiovascular computed tomography: integration in clinical care as a prognostic medical device. Cardiovascular Research 117: 2677–2690
Tsiachristas A, Chan K, Wahome E et al. (2025) Cost-effectiveness of a novel AI technology to quantify coronary inflammation and cardiovascular risk in patients undergoing routine coronary computed tomography angiography. European Heart Journal - Quality of Care and Clinical Outcomes 11(4): 434–444
ISBN: 978-1-4731-7323-1
This page was last updated: